Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

Learn More
Latest News

Committed to Supporting Clients During the COVID-19 Pandemic

Access resources and information related to COVID-19 studies to discover how we are joining the COVID-19 fight

Learn More
Upcoming Webinar

Advancing Early Stage Oncology Research with Adaptive Designs and Master Protocols

Tuesday, September 29, 2020 | 10:00AM EDT

Register Now
ebook

Version 4.1 of the AMCP Format: Introducing a Trio of Dossiers to Support a Product Throughout its Lifecycle

Gain insight into Version 4.1 of the AMCP Format for Formulary Submissions, which describes three types of dossiers that manufacturers may choose to develop

Read Now
Upcoming Webinar

Enhancing Interpretation of Clinical Trial Outcomes: Are We Listening to Trial Participants?

Thursday, October 8, 2020 | 10:00AM EDT

Register Now
Upcoming Webinar Series

Global Genes Three-Part Webinar Series

Discover five core guiding principles to use as a set of fundamental expectations for rare disease patient care and access
Co-sponsored by Global Genes and the Child Neurology Foundation in partnership with NAMCP

Learn More

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2018 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

Any

Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group

  • Value Health
  • September 2020
Cardiovascular

Utility Value Estimates in Cardiovascular Disease and the Effect of Changing Elicitation Methods: A Systematic Literature Review

  • Health Qual Life Outcomes
  • September 2020
Surgery

Regenerative Medicine and Cell Therapy in Orthopedics – Health Policy, Regulatory and Clinical Development, and Market Access

  • Techniques in Orthopaedics
  • September 2020
Read More About Our Publications
What We Do

What We Do

Real-World Evidence

Obtain real-world evidence of value by extracting data from existing sources, collecting primary data, and conducting hybrid studies.

Patient-Centered Research

Develop and evaluate clinical outcomes assessments to support labeling and promotional claims.

Evidence Synthesis, Modeling & Communication

Provide a truly connected value story, supported by strong evidence

Value & Development Consulting

Optimize market access with cogent payer insights, expert-informed evidence strategy, and persuasive communication of product value.

Interventional Studies

Provide peri- and post-approval evidence via dedicated global operations and custom-tailored study designs.

Pragmatic Studies

Explore patient-centered outcomes and comparative effectiveness using pragmatic studies with adaptive designs.

Medical Writing

Expert medical writing, including medical information, study documentation, and publications, tailored to the peri- and post-approval environment.

In Our Own Words

A virtual or decentralized approach puts the focus where it should be—on the patients. Our decentralized approach and study innovations maximize data collection while minimizing burden to patients, caregivers, and healthcare providers to answer important research questions.

Case Study

Virtual Expanded Access Program Providing Breast Cancer Patients Early Access to Treatment During the COVID-19 Pandemic

Evidera was able to provide a virtual approach to mitigate the risk to patient safety in the COVID-19 pandemic and enabled early patient access to 400 US breast cancer patients ahead of commercial availability.

Read More
Case Study

Enhancing Oncology Market Access with a Real-World Evidence EAMS Add-on

Discover how Evidera researchers designed an observational study to conceptualize and implement real-world data collection in an Early Access to Medicines Scheme (EAMS) for an oncology therapy.

Read More
Case Study

Evidera Led Effort to Qualify the First Biomarker for COPD Trial Enrichment

Learn how Evidera's partnership with the COPD Foundation Biomarker Qualification Consortium led to the qualification of plasma fibrinogen as the first biomarker in COPD for enrichment of clinical trials by the FDA.

Read More
Careers

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More